In last trading session, Kymera Therapeutics Inc (NASDAQ:KYMR) saw 0.59 million shares changing hands with its beta currently measuring 2.20. Company’s recent per share price level of $38.17 trading at -$2.35 or -5.80% at ring of the bell on the day assigns it a market valuation of $2.47B. That closing price of KYMR’s stock is at a discount of -39.56% from its 52-week high price of $53.27 and is indicating a premium of 33.3% from its 52-week low price of $25.46. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.4 million shares which gives us an average trading volume of 431.67K if we extend that period to 3-months.
For Kymera Therapeutics Inc (KYMR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.79 in the current quarter.
Kymera Therapeutics Inc (NASDAQ:KYMR) trade information
Upright in the red during last session for losing -5.80%, in the last five days KYMR remained trading in the red while hitting it’s week-highest on Monday, 01/06/25 when the stock touched $38.17 price level, adding 11.73% to its value on the day. Kymera Therapeutics Inc’s shares saw a change of -5.12% in year-to-date performance and have moved -6.65% in past 5-day. Kymera Therapeutics Inc (NASDAQ:KYMR) showed a performance of -12.55% in past 30-days. Number of shares sold short was 8.79 million shares which calculate 18.77 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 57 to the stock, which implies a rise of 33.04% to its current value. Analysts have been projecting 55 as a low price target for the stock while placing it at a high target of 65. It follows that stock’s current price would drop -44.09% in reaching the projected high whereas dropping to the targeted low would mean a loss of -44.09% for stock’s current value.
Kymera Therapeutics Inc (KYMR) estimates and forecasts
Statistics highlight that Kymera Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -2.13% of value to its shares in past 6 months, showing an annual growth rate of -10.71% while that of industry is 16.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2025. This year revenue growth is estimated to fall -31.51% from the last financial year’s standing.
18 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 14.81M for the same. And 9 analysts are in estimates of company making revenue of 16.59M in the next quarter. Company posted 47.88M and 10.29M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -39.18% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -11.96% while estimates for its earnings growth in next 5 years are of 1.90%.
Kymera Therapeutics Inc (NASDAQ:KYMR)’s Major holders
Insiders are in possession of 1.27% of company’s total shares while institution are holding 108.20 percent of that, with stock having share float percentage of 109.60%. Investors also watch the number of corporate investors in a company very closely, which is 108.20% institutions for Kymera Therapeutics Inc that are currently holding shares of the company. PRICE T ROWE ASSOCIATES INC /MD/ is the top institutional holder at KYMR for having 6.39 million shares of worth $190.76 million. And as of 2024-06-30, it was holding 9.0301 of the company’s outstanding shares.
The second largest institutional holder is BAKER BROS. ADVISORS LP, which was holding about 6.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.4724 of outstanding shares, having a total worth of $178.98 million.
On the other hand, Price (T.Rowe) New Horizons Fund and Vanguard Specialized-Health Care Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 3.14 shares of worth $119.89 million or 4.85% of the total outstanding shares. The later fund manager was in possession of 2.12 shares on Oct 31, 2024 , making its stake of worth around $80.8 million in the company or a holder of 3.27% of company’s stock.
